Sinotherapeutics (SH:688247) Ge Long Hui·2026-02-27 08:09Core Viewpoint - Xuantai Pharmaceutical (688247.SH) reported a significant decline in both revenue and net profit for the year 2025, primarily due to price reductions in domestic drug procurement policies and increased competition in overseas markets [1] Financial Performance - The company achieved total operating revenue of 446.49 million yuan, a year-on-year decrease of 12.73% [1] - The net profit attributable to the parent company was 48.95 million yuan, down 61.67% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 31.38 million yuan, reflecting a 72.47% year-on-year decline [1] Market Conditions - Domestic drug procurement policies have led to significant price reductions for some of the company's products, resulting in narrowed profit margins [1] - In overseas markets, the company faced intensified industry competition and adjustments in tariff policies, leading to a decline in sales and profitability of related products compared to the previous year [1] Impairment Losses - The company, following a cautious approach, recognized impairment losses on accounts receivable, inventory, and goodwill in accordance with relevant accounting standards, negatively impacting the current net profit [1]